{"id":"placebo-for-anacetrapib","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1800807","moleculeType":"Small molecule","molecularWeight":"637.51"},"_fixedAt":"2026-03-30T12:13:08.166847","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (anacetrapib) through comparison. It contains no active pharmaceutical ingredient and produces no direct therapeutic effect beyond potential placebo response.","oneSentence":"This is a placebo control with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:56.931Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in anacetrapib clinical trials for dyslipidemia/cardiovascular risk reduction"}]},"_fixedFields":["pubmed(46)"],"trialDetails":[{"nctId":"NCT01860729","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-05-13","conditions":"Hypercholesterolemia","enrollment":589},{"nctId":"NCT01524289","phase":"PHASE3","title":"Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-03","conditions":"Hyperlipoproteinemia Type II, Hypercholesterolemia, Familial","enrollment":306},{"nctId":"NCT00685776","phase":"PHASE3","title":"Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03-24","conditions":"Coronary Heart Disease (CHD), CHD Risk-Equivalent Disease","enrollment":1623},{"nctId":"NCT01760460","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-03-14","conditions":"Dyslipidemia","enrollment":307},{"nctId":"NCT01717300","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-06","conditions":"Hypercholesterolemia","enrollment":459},{"nctId":"NCT01824238","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-05","conditions":"Heterozygous Familial Hypercholesterolemia (HeFH)","enrollment":68},{"nctId":"NCT00990808","phase":"PHASE1","title":"The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Dyslipidemia","enrollment":46},{"nctId":"NCT01841684","phase":"PHASE3","title":"Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06","conditions":"Hyperlipoproteinemia Type II, Homozygous Familial Hypercholesterolemia","enrollment":2},{"nctId":"NCT00977288","phase":"PHASE2","title":"A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09","conditions":"Dyslipidemia","enrollment":408}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"recentPublications":[{"date":"2026 Jan 19","pmid":"41549108","title":"Comparative efficacy of obicetrapib and anacetrapib in reducing low-density lipoprotein (LDL) levels: a network meta-analysis of clinical trials.","journal":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences"},{"date":"2025 Sep","pmid":"40947782","title":"Comparative Effectiveness of Cholesteryl Ester Transfer Protein (CETP) Inhibitors on Lipid Profiles in Adults With Hyperlipidemia: A Comprehensive Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials.","journal":"Clinical cardiology"},{"date":"2024 May 16","pmid":"38786974","title":"Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.","journal":"Journal of cardiovascular development and disease"},{"date":"2023 Jan","pmid":"36410424","title":"Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans.","journal":"Journal of lipid research"},{"date":"2022 Apr 6","pmid":"34910136","title":"Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.","journal":"European heart journal"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for anacetrapib","genericName":"Placebo for anacetrapib","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anacetrapib is a small molecule inhibitor of cholesteryl ester transfer protein, a drug class that targets this specific protein. In clinical trials, anacetrapib was compared to a placebo in treating conditions such as hyperlipoproteinemia type II, homozygous familial hypercholesterolemia, and hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}